Navigation Links
Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO)
Date:1/12/2009

mittal and related tender offer documents) and the related solicitation/recommendation statement that will be filed by AMO with the SEC, because they will contain important information. These documents will be available at no charge on the SEC's Web site at http://www.sec.gov.

AMO Forward-Looking Statements

Statements in this press release that refer to AMO's estimated or anticipated future results such as statements from management, statements in the "Financial Terms" section and statements regarding business expectations are forward looking statements. All forward-looking statements by AMO in this press release reflect AMO's current analysis of existing trends and information and represent AMO's judgment only as of the date of this press release. Actual results may differ from current expectations based on a number of factors affecting AMO's businesses including but not limited to the impact of the global economic downturn; unexpected changes in competitive, regulatory and market conditions; the performance of new products and the continued acceptance of current products; the execution of strategic initiatives; AMO's ability to maintain a sufficient supply of products; litigation; and unexpected delays or impediments to the announced transaction.

In addition, matters generally affecting the domestic and global economy, such as changes in interest and currency exchange rates or consumer confidence indices, can affect AMO's results. Therefore, the reader is cautioned not to rely on these forward-looking statements. AMO disclaims any intent or obligation to update these forward-looking statements. Additional information concerning these and other risk factors may be found in previous financial press releases issued by AMO. AMO's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Fa
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Abbott Announces Earnings Guidance for 2009
2. Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
3. Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis
4. Abbotts XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award
5. Abbott Hosts Conference Call for Third-Quarter Earnings
6. Abbott to Present at UBS Best of Americas Investment Conference
7. Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology
8. Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
9. Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
10. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
11. Abbott Invests Additional $20M in Isis Subsidiary Ibis Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... -- InferMed , s ... will augment ... olutions suite   Elsevier , a ... services, announced today the acquisition of  InferMed , a ... InferMed,s Arezzo technology supports clinicians in choosing the ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... pathogen transmission. CTI’ new Medical Joysticks have an impermeable molecular barrier protection ... an operator control device that will increase healthcare worker safety and reduce financial ...
(Date:6/30/2015)... Japan , July 1, 2015 R-Japan Co.,Ltd. ... on the Safety of Regenerative Medicine from the Ministry of ... on June 29, 2015. The fact that ... processing facility through the auditing from Pharmaceuticals and Medical Devices ... the application, allows it to provide stem cell manufacturing service ...
(Date:6/30/2015)... June 30, 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") ... shares of Resverlogix have approved the resolutions relating ... Limited of 5,600,000 units at a price of ... unit being comprised of one common share and ... of approximately CAD$15 million; and (ii) the amendment ...
Breaking Biology Technology:Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3
... European Partnerships, ALAMEDA, Calif., and PARIS, March ... Novartis Pharma AG to give Novartis,access to Singulex,s ... Program (ETAP). Terms of the collaboration,were not disclosed. ... a,facility in Paris, France to support the needs ...
... March 6 VaxGen,Inc. (Pink Sheets: VXGN), a biopharmaceutical ... recent cash balance, with a view to,ensuring that stockholders ... the company,s proposed merger with Raven biotechnologies,inc. VaxGen,s Board ... date for the,Special Meeting of Stockholders to vote on ...
... Conference call scheduled for March 13, 2008 at 1:30 p.m. (Pacific); ... simultaneous webcast at http://www.adventrx.com , ... today announced that it will host a conference call and,webcast on ... to discuss fourth quarter and year end 2007 results. Evan M.,Levine, ...
Cached Biology Technology:Singulex Collaborates With Large Pharmaceutical Company in Erenna(TM) Technology Access Program 2VaxGen Reports Financial Update 2VaxGen Reports Financial Update 3VaxGen Reports Financial Update 4VaxGen Reports Financial Update 5VaxGen Reports Financial Update 6VaxGen Reports Financial Update 7
(Date:6/26/2015)... SPRINGVILLE, Utah , June 26, 2015 ATL ... assemblies and devices with specialties in single use solutions, headquartered ... acquisition of MedConx, Inc. (a California ... , and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing ...
(Date:6/24/2015)... NEW YORK , June 24, 2015 ... favorable rate. The major drivers for the market include ... increasing number of new drug launches. Over the years, ... has increased. Between 2001 and 2010, the FDA approved ... addition, according to WIPO, Europe ...
(Date:6/24/2015)... 24, 2015 Biometry authentication provider KeyLemon ... password solution one face in. ... one face in, entering the expanding biometric authentication ... multifactor-authentication biometric answer to the password problem. With ... partnership with KeyLemon, one face in allows users ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... bring forth the best properties of both ever since ... Age. In the latest successful merger, researchers at the ... of Maryland (UM) and the U.S. Food and Drug ... substances that individually have generated interest for their potential ...
... SALT LAKE CITY An international consortium of researchers ... has reported that a study of nearly 2,300 people supports ... rare genetic changes called copy number variants (CNVs). The ... the Autism Genome Project (AGP), were published in Nature on ...
... - Researchers have discovered precisely why strands of some ... stretched, findings that could be used to improve industrial ... "Any kindergartner is familiar with this beading phenomenon, which ... between your thumb and forefinger," said Osman Basaran, Purdue,s ...
Cached Biology News:Liposome-hydrogel hybrids: No toil, no trouble for stronger bubbles 2Autism genome project identifies genetic variants that may make people susceptible to disorder 2Solution to beading-saliva mystery has practical purposes 2Solution to beading-saliva mystery has practical purposes 3
Inquire...
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
Rb anti-Occludin (C-term GST)...
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
Biology Products: